There's no industrial biocatalyst like hydrolase: Development of scalable enantioselective processes using hydrolytic enzymes

Organic Process Research and Development

Volumn 7, Issue 3, 2003, Pages 289-296

  Chikusa, Yasuo ^a,c   Hirayama, Yoshihiro ^a   Ikunaka, Masaya ^a   Inoue, Toru ^a   Kamiyama, Shunji ^a   Moriwaki, Masafumi ^a   Nishimoto, Yukifumi ^a   Nomoto, Fumiki ^a   Ogawa, Kazuo ^b   Ohno, Tomoyasu ^b   Otsuka, Koutaro ^a   Sakota, Akiko K ^a   Shirasaka, Naoki ^a   Uzura, Atsuko ^a   Uzura, Kensaku ^c  

^a Osaka City University Medical School   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c Nagase Chemtex Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYLOXY 3 CHLOROPROPAN 2 YLHYDROGEN SUCCINATE; 2 METHOXYETHYL 1 (4 TERT BUTYLPHENYL) 2 OXOPYRROLIDINE CARBOXYLATE; 3 BUTYRYLOXYQUINUCLIDINIUM BUTYRATE; 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXYLATE METHYL ESTER; ALPHA PHENYLPROPIONATE METHYL ESTER; BACTERIAL ENZYME; ESTER DERIVATIVE; ESTERASE; FUNGAL ENZYME; HYDRATROPIC ACID; HYDROLASE; PROTEIN HYDROLYSATE; PROTEINASE; TETRAHYDROFURAN 2 CARBOXYLATE ETHYL ESTER; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLUS; ASPERGILLUS MELLEUS; BACILLUS BREVIS; BIOCATALYST; CATALYSIS; CHIRALITY; CONCENTRATION (PARAMETERS); ENANTIOSELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HYDROLYSIS; KLEBSIELLA OXYTOCUM; RACEMIC MIXTURE; SEPARATION TECHNIQUE; SERRATIA MARCESCENS;

EID: 0037708583     PISSN: 10836160     EISSN: None     Source Type: Journal    
DOI: 10.1021/op034014b     Document Type: Article

References (53)

1. This is an enlarged and combined transcript based on two lectures: Stereoselective Synthesis of Chiral Pharmaceutical Intermediates (The Fourth International Conference on Organic Process Research and Development, Hong Kong, March 18-21, 2001) and Scalable Enantioselective Processes for Chiral Carboxylic Acids (The Fifth International Conference on the Scale-up of Chemical Processes, Jersey, U.K., September 23-26, 2002). For the other parts of the lectures and other papers at the conferences, contact Scientific Update, Maycroft Place, Stone Cross, Mayfield, East Sussex TN20 6EW, United Kingdom; Telephone: +44 1435 873062; Fax: +44 1435 872734; E-mail: sciup@scientificupdate.co.uk.
2. Bornsheuer, U. T.; Kazlauskas, R. J. Hydrolases in Organic Synthesis: Regio- and Stereoselective Biotransformations; Wiley-VCH: Weinheim, 1999.
3. Liese, A.; Seelbach, K.; Wandrey, C. Industrial Biotransformations; Wiley-VCH: Weinheim, 2000.
4. (a) Bornsheuer, U. T.; Kazlauskas, R. J. Hydrolases in Organic Synthesis: Regio- and Stereoselective Biotransformations; Wiley-VCH: Weioheim, 1999; pp 32-33.
5. (b) Wong, C.-H.; Whitesides, G. M. Enzymes in Synthetic Organic Chemistry; Pergamon: Oxford, 1994; pp 9-13.
6. For the inhibition caused not by a leaving group, such as L 3, but by a resolved product, such as -2, see: (a) Akeboshi, T.; Ohtsuka, Y.; Ishihara, T.; Sugai, T. Adv. Synth. Catal. 2001, 343, 624.
7. (b) Lundhaug, K.; Overbeeke, P. L. A.; Jongejan, J. A.; Anthonsen, T. Tetrahedron: Asymmetry 1998, 9, 2851.
8. (a) Nishino, T.; Maeda, Y.; Ohtsu, E.; Koizuka, S.; Nishihara, T.; Adachi, H.; Okamoto, K.; Ishiguro, M. J. Antibiot. 1989, 42, 977.
9. (b) For a concise review on synthetic approaches to nonclassical β-lactam antibiotics, see: Carbi, W.; Di Fabio, R. From Bench to Market: The Evolution of Chemical Synthesis; Oxford University Press: Oxford, 2000; pp 25-47.
10. (a) Bélanger, P. C.; Williams, H. W. R. Can. J. Chem. 1983, 61, 1383.
11. (b) Cervinka, O.; Bajanzulyn, O.; Fábryová, Šačuks, A. Collect. Czech. Chem. Commun. 1986, 51, 404.
12. (c) Nohira, H.; Nagata, A.; Kondo, M.; Takebayashi, A. Jpn. Kokai Tokkyo Koho 89 216,983, 1989.
13. (d) Nakai, S.; Sato, H.; Fujino, T. (Toray Industries, Inc.). Jpn. Kokai Tokkyo Koho 96 59,517, 1996.
14. (e) van Eikeren, P.; McConville, F. X.; Lopez, J. (Sepracor, Inc.). WO 96/36,584, 1996.
15. Available from Nagase ChemteX Corporation. Telephone: +81 773 27 3495. Fax: +81 773 27 6450. E-mail: kensaku.uzura@ncx.nagase.co.jp.
16. (a) Nishimoto, Y.; Hirayama, Y.; Fujima, Y.; Ikunaka, M. (Nagase & Co., Ltd.). Jpn. Kokai Tokkyo Koho 2002 171,994, 2002.
17. (b) For the influence of reaction parameters on both kinetics and enantioselectivity of the enzymatic reaction, see: Fujima, Y.; Hirayama, Y.; Ikunaka, M.; Nishimoto, Y. Tetrahedron: Asymmetry 2003, 14, in press.
18. Stahly, G. P.; Starrett, R. M. Production Methods for Chiral Non-steroidal Anti-inflammatory Profen Drugs. In Chirality in Industry II: Developments in the Commercial Manufacture and Applications of Optically Active Compounds; Collins, A. N., Sheldrake, G. N., Crosby, J., Eds.; John Wiley & Sons: Chichester, 1997; pp 19-40.
19. For the resolution of typical profens such as (±)-ibuprofen, (±)-ketoprofen, and (±)-naproxen into the respective (S)-enantiomers via diastereomeric salt formation with (S)-3-methyl-2-phenylbutylamine, see: Chikusa, Y.; Fujimoto, T.; Ikunaka, M.; Inoue, T.; Kamiyama, S.; Maruo, K.; Matsumoto, J.; Matsuyama, K.; Moriwaki, M.; Nohira, H.; Saijo, S.; Yamanishi, M.; Yoshida, K. Org. Process Res. Dev. 2002, 6, 291.
20. Uzura, K.; Uzura, A.; Saegusa, M. (Nagase & Co., Ltd.). Jpn. Tokkyo Koho (Jpn. Patent) 3,093,039, 2000.
21. Nomoto, F.; Kuramura, A.; Uzura, K. (Nagase & Co., Ltd.). Jpn. Kokai Tokkyo Koho 97 275,982, 1997.
22. For an available sample of the K. oxytoca hydrolase, contact the corresponding author.
23. Nohira, H.; Aoki, Y.; Yokokoji, O.; Isono, K. (Seimi Chemical Co., Ltd.). Jpn. Kokai Tokkyo Koho 98 251,185, 1998.
24. Ikunaka, M.; Matsumoto, J.; Fujima, Y.; Hirayama, Y. Org. Process Res. Dev. 2002, 6, 49.
25. Ikunaka, M.; Matsumoto, J.; Nishimoto, Y. Tetrahedron: Asymmetry 2002, 13, 1201.
26. For other applications of the K. oxytoca hydrolase, see: (a) Kimura, M.; Kuboki, A.; Sugai, T. Tetrahedron: Asymmetry 2002, 13, 1059.
27. (b) Kiyota, H.; Nakabayashi, M.; Oritani, T. Tetrahedron: Asymmetry 1999, 10, 3811.
28. (a) Watanabe, S.; Ogawa, K.; Ohno, T.; Yano, S.; Yamada, H.; Shirasaka, T. Eur. J. Med. Chem. 1994, 29, 675.
29. (b) Ohno, T.; Yano, S.; Yamada, H.; Shirasaka, T.; Yamamoto, A.; Kobayashi, K.; Ogawa, K. Chem. Pharm. Bull. 1999, 47, 1549.
30. Otsuka, K.; Kamiyama, S.; Moriwaki, M. (Taiho Pharmaceutical Co., Ltd. and Nagase & Co., Ltd.). Jpn. Kokai Tokkyo Koho 99 113,594, 1999.
31. (a) Takano, S. Yakugaku Zasshi 1991, 111, 647.
32. (b) Takano, S.; Sekiguchi, Y.; Setoh, M.; Yoshimitsu, T.; Inomata, K.; Takahashi, M.; Ogasawara, K. Hetrocycles 1990, 31, 1715.
33. (a) Pedersen, R. L.; Liu, K. K.-C.; Rutan, J. F.; Chen, L.; Wong, C.-H. J. Org. Chem. 1990, 55, 4897.
34. Partali, V.; Waagen, V.; Alvik, T.; Anthonsen, T. Tetrahedron: Asymmetry 1993, 4, 961.
35. Otsuka, K.; Yamamoto, C.; Umezato, T.; Kamiyama, S. (Nagase & Co., Ltd.). Jpn. Kokai Tokkyo Koho 97 140,394, 1997.
36. For an ingenious design of enzymatic transesterification based on a related concept, see: Cantele, F.; Restelli, A.; Riva, S.; Tentorio, D.; Villa, M. Adv. Synth. Catal. 2001, 343, 721.
37. Bjørsvik, H.-R.; Liguori, L.; Costantino, F.; Minisci, F. Org. Process Res. Dev. 2002, 6, 197.
38. Moore, B. A.; Keir, R. F.; Stuart, E. F.; Stobie, A.; Wright, K. N. Eur. Respir. J. 1996, 9 (Suppl. 23), Abs. PO261.
39. Leusch, A.; Tröger, W.; Greischel, A.; Roth, W. Xenobiotica 2000, 30, 797.
40. For a relevant approach using subtilisin Carlsberg, see: (a) Muchmore, D. C. (Bend Research, Inc.). U.S. Patent 5,215,918, 1993.
41. (b) Spec. Chem. Mag. 2001, July/August, 14.
42. (c) Nomoto, F.; Otsuka, K. (Nagase & Co., Ltd.). Jpn. Kokai Tokkyo Koho 98 210,997, 1998.
43. (d) This subject will be discussed in depth with experimental details elsewhere: Nomoto, F.; Hirayama, Y.; Ikunaka, M.; Inoue, T.; Otsuka, K. Tetrahedron: Asymmetry. Manuscript submitted.
44. For the reuse of (S)-20a via its oxidation to quinuclidin-3-one 23, see ref 25.
45. (b) Sternbach, L. H.; Kaiser, S. J. Am. Chem. Soc. 1952, 74, 2215.
46. For the synthesis of 23, the immediate precursor to (±)-20a, see: Daeniker, H. U.; Grob, C. A. Organic Syntheses; John Wiley & Sons: New York, 1973; Collect. Vol. V, p 989.
47. Ebbers, E. J.; Ariaans, G. J. A.; Houbiers, J. P. M.; Bruggink, A. Zwanenburg, B. Tetrahedron 1997, 53, 9417.
48. (a) Nomoto, F.; Hirayama, Y.; Inoue, T. (Nagase & Co., Ltd.). Jpn. Tokkyo Kokai Koho 99 246,558, 1999.
49. (b) For other application of Raney Co-catalyzed racemization, see: Fujii, A.; Fujima, Y.; Harada, H.; Ikunaka, M.; Inoue, T.; Kato, S.; Matsuyama, K. Tetrahedron: Asymmetry 2001, 12, 3235.
50. For the comprehensive discussion on route selection, see: Ikunaka, M. Chem. - Eur. J. 2003, 9, 378.
51. For the enatioconvergent chemoenzymatic processes, see: Hirohara, H.; Nishizawa, M. Biosci. Biotechnol. Biochem. 1998, 62, 1.
52. (a) For the separation between an alcohol and an ester thereof via O-sulfation of the former, see: Yamano, T.; Kikumoto, F.; Yamamoto, S.; Miwa, K.; Mizuno, Y. Chem. Lett. 2000, 448.
53. (b) For the separation tactics employing hydrogen phthalate formation, see: Lloyd, R. C.; Smith, M. E. B.; Brick, D.; Taylor, S. J. C.; Chaplin, D. A.; McCague, R. Org. Process Res. Dev. 2002, 6, 762.